The company that invented Aspirin in 1899 spent $63 billion to buy the world’s most controversial seed company, survived the litigation that followed, and is now rebuilding around oncology and cardiovascular breakthroughs. Bayer AG posted $49.2 billion in revenue in 2025 across pharmaceuticals, crop science, and consumer health,three businesses under one roof, 88,078 employees, 163 years of continuous operation.
Friedrich Bayer and Johann Friedrich Weskott founded a dyestuffs factory in Barmen, Germany, in 1863. Within four decades, that factory’s chemists had synthesized acetylsalicylic acid and registered it under the brand name Aspirin. It became the most widely used medicine in human history. That single molecule established the template for what a pharmaceutical company could be: a chemical enterprise that discovers, patents, manufactures, and markets compounds at global scale. Everything that followed in the industry,blockbuster drugs, patent cliffs, lifecycle management,traces a line back to what Bayer did with Aspirin.
But the modern Bayer story is not really about Aspirin. It is about a series of structural bets that transformed a diversified chemicals conglomerate into a focused life sciences company. In 2014, Bayer had $45.6 billion in revenue, 118,888 employees, and a materials science division that made polycarbonate plastics. By 2015, the company had agreed to spin off that division as Covestro, concentrating entirely on pharmaceuticals, crop science, and consumer health. Revenue hit a record $50.0 billion that year with 116,800 employees. The company was betting that its future lay in life sciences, not polymers.
Then came the acquisition that would define the next decade.
In September 2016, Bayer agreed to acquire Monsanto for $63 billion. It was the largest all-cash takeover in corporate history at the time, and it turned Bayer into the world’s largest agricultural company overnight. The logic was straightforward: combine Bayer’s crop protection chemicals with Monsanto’s seed genetics and digital farming platforms to create an integrated agricultural sciences powerhouse. The deal closed in June 2018. Revenue jumped to $42.8 billion with 117,000 employees as Monsanto’s operations were absorbed.
What Bayer also acquired was the glyphosate litigation. Monsanto’s Roundup herbicide, the most widely used weedkiller on earth, faced tens of thousands of lawsuits alleging that glyphosate caused non-Hodgkin lymphoma. Bayer inherited every one of those claims. The company that had spent 155 years building a reputation for scientific rigour found itself defending a product it had not invented, in courtrooms across America, against juries that did not distinguish between the German parent and the Missouri subsidiary it had purchased.
By 2019, revenue had climbed to $47.0 billion, but the litigation was exacting a toll that went beyond legal costs. Bayer’s market capitalization fell below the price it had paid for Monsanto alone. In 2020, the company agreed to settle the bulk of the Roundup litigation for more than $10 billion. The settlement did not end all claims, but it stopped the bleeding. Revenue that year was $44.7 billion with 99,538 employees,the workforce already shrinking as integration efficiencies took hold.
The Monsanto acquisition reshaped Bayer in ways that the deal architects did not fully anticipate. It made Bayer number one in agriculture globally. It also made Bayer the subject of more product liability litigation than any pharmaceutical company in modern history. Whether the trade was worth it depends on the time horizon. In 2022, Bayer posted a record $54.8 billion in revenue, with the crop science division delivering its strongest performance ever. By 2023, net losses of $2.9 billion from impairments told a different story.
Numbers reveal priorities. Among all OPPI member companies filing patents in India, Bayer holds the second-highest total count at 1,864 filings and the highest grant count at 224 patents granted. Those filings span from 1994 to 2026, covering three decades of Indian patent law,from the pre-TRIPS era through the 2005 product patent regime and into the current system of compulsory licensing debates and Section 3(d) challenges.
The breadth of Bayer’s India patent portfolio reflects its three-division structure. Unlike purely pharmaceutical OPPI members, Bayer files patents across human health, crop science, and materials innovation. Xarelto formulations sit alongside glyphosate-tolerant seed traits and polymer compositions. This diversification means Bayer’s India IP strategy is not a single pipeline bet but a portfolio play covering multiple patent offices, multiple technical fields, and multiple enforcement jurisdictions within Indian law.
A 12 per cent grant rate,224 out of 1,864,is notable in the Indian patent system, where examination backlogs, pre-grant oppositions, and the stringent Section 3(d) efficacy standard combine to make India one of the more demanding jurisdictions for pharmaceutical patents globally. That Bayer has secured more grants than any other OPPI member suggests a filing strategy calibrated to Indian patent office expectations: claims drafted for the jurisdiction, not merely transplanted from European or US applications.
Bayer’s structure is unique among OPPI members. No other company in the organization operates at scale across pharmaceuticals, agriculture, and consumer health simultaneously. The pharmaceuticals division produces Xarelto (rivaroxaban), the oral anticoagulant that became one of the best-selling drugs in history, alongside Eylea (aflibercept) for macular degeneration, Stivarga (regorafenib) and Xofigo (radium-223) in oncology, and Adempas (riociguat) for pulmonary hypertension. The pipeline in 2025 centres on blockbuster oncology and cardiovascular candidates.
The crop science division,dramatically enlarged by Monsanto,sells seeds, traits, and crop protection products to farmers on every arable continent. This is the division that makes Bayer the world’s largest agricultural company, and it is also the division most exposed to commodity cycles, weather risk, and regulatory shifts. In 2024, crop science challenges contributed to declining group EBITDA even as revenue held at $50.3 billion.
Consumer health rounds out the portfolio with over-the-counter brands that most people do not associate with Bayer the conglomerate: Aspirin, Aleve, Claritin, Bepanthen. These products generate steady cash flows with lower R&D intensity than the pharmaceutical pipeline but face the margin pressure of consumer-goods competition.
The question that has followed Bayer for the past five years is whether this structure creates value or destroys it. Investors have periodically called for a breakup. In 2023, Bayer launched its Dynamic Shared Ownership transformation,a fundamental restructuring of how the company operates, pushing decision-making authority downward and eliminating management layers. It was an acknowledgment that a company operating across three distinct industries needed to move faster than its conglomerate structure historically allowed.
Sources: Bayer Annual Reports 2014–2025. Indian Patent Office (patent filing and grant data). OPPI member directory.